Cargando…
Perception of various stakeholders regarding clinical drug trial industry in India
CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications Pvt Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159214/ https://www.ncbi.nlm.nih.gov/pubmed/21897882 http://dx.doi.org/10.4103/2229-3485.83225 |
_version_ | 1782210426066436096 |
---|---|
author | Parikh, Rakesh M. Pandia, Kirti Goyal, Mahesh Sharma, Meenakshi Dolima, M. S. |
author_facet | Parikh, Rakesh M. Pandia, Kirti Goyal, Mahesh Sharma, Meenakshi Dolima, M. S. |
author_sort | Parikh, Rakesh M. |
collection | PubMed |
description | CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions. MATERIALS AND METHODS: An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. RESULTS: Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. CONCLUSIONS: Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations. |
format | Online Article Text |
id | pubmed-3159214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Medknow Publications Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31592142011-09-06 Perception of various stakeholders regarding clinical drug trial industry in India Parikh, Rakesh M. Pandia, Kirti Goyal, Mahesh Sharma, Meenakshi Dolima, M. S. Perspect Clin Res Original Article CONTEXT: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. AIMS: There is an urgent need for introspection and corrective actions. MATERIALS AND METHODS: An online survey was conducted among various stakeholders from clinical drug trial industry in India regarding their perception about clinical drug trial industry in India. Respondents were requested to rate training of investigator sites, industry, performance of regulatory, etc. RESULTS: Majority of respondent felt that the clinical drug trial industry in India is growing, though India is not utilizing its full potential. Lack of trained investigators and delay in regulatory approvals came out as biggest hurdles. CONCLUSIONS: Urgent steps need to be taken in terms of proper training of all stakeholders. Regulatory bodies ought to bring about some radical changes in the system so as to match the other competing nations. Medknow Publications Pvt Ltd 2011 /pmc/articles/PMC3159214/ /pubmed/21897882 http://dx.doi.org/10.4103/2229-3485.83225 Text en Copyright: © Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Parikh, Rakesh M. Pandia, Kirti Goyal, Mahesh Sharma, Meenakshi Dolima, M. S. Perception of various stakeholders regarding clinical drug trial industry in India |
title | Perception of various stakeholders regarding clinical drug trial industry in India |
title_full | Perception of various stakeholders regarding clinical drug trial industry in India |
title_fullStr | Perception of various stakeholders regarding clinical drug trial industry in India |
title_full_unstemmed | Perception of various stakeholders regarding clinical drug trial industry in India |
title_short | Perception of various stakeholders regarding clinical drug trial industry in India |
title_sort | perception of various stakeholders regarding clinical drug trial industry in india |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159214/ https://www.ncbi.nlm.nih.gov/pubmed/21897882 http://dx.doi.org/10.4103/2229-3485.83225 |
work_keys_str_mv | AT parikhrakeshm perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia AT pandiakirti perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia AT goyalmahesh perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia AT sharmameenakshi perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia AT dolimams perceptionofvariousstakeholdersregardingclinicaldrugtrialindustryinindia |